NCT03768570
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
StatusActive, Not Recruiting
PhasePhase 2
SponsorCanadian Cancer Trials Group
Primary completion (estimated)
At risk: Primary completion moved 5 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 45 versions: 40 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 50 words Show 4 more changesShow less
- Primary completion pushed from Oct 31, 2026 to Mar 31, 2027
- Study completion pushed from Dec 31, 2026 to Jun 30, 2027
- Secondary endpoints: details revised at 4 of 9 entries
- Site details revised at 6 of 31 sites
- Minor Primary completion pushed from Jun 30, 2026 to Oct 31, 2026v44
- Notable Primary completion date: Dec 31, 2025 to Jun 30, 2026
- Study completion date: Mar 31, 2026 to Dec 31, 2026
- Minor Primary completion date: Jul 31, 2025 to Dec 31, 2025v42
- Minor Primary completion date: Mar 31, 2025 to Jul 31, 2025v41
Show 34 earlier versionsHide 34 earlier versions
- Notable Start date: Dec 21, 2018 to Oct 25, 2019v39
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 190 to confirmed 82
- Site details revised at 31 of 31 sites
- Minor Study sites: 30 to 31v37
- Minor Site contacts updated at 1 of 30 sitesv36
- Minor Study sites: 29 to 30v35
- Minor Study sites: 28 to 29v34
- Minor Study sites: 27 to 28v33
- Minor Site details revised at 1 of 27 sitesv32
- Minor Site details revised at 2 of 27 sitesv31
- Minor Study sites: 26 to 27v30
- Notable Primary completion date: Dec 31, 2023 to Mar 31, 2025
- Enrollment target: 238 to 190
- Study completion date: Dec 31, 2024 to Mar 31, 2026
- Minor Study sites: 25 to 26v27
- Minor Study sites: 24 to 25v26
- Minor Study sites: 23 to 24v25
- Minor Study sites: 20 to 23
- Secondary endpoints: details revised at 1 of 9 entries
- Notable Eligibility criteria expanded, about 7 wordsv23
- Minor Study sites: 21 to 20v22
- Minor Study sites: 20 to 21v19
- Minor Study sites: 16 to 20v18
- Minor Site details revised at 2 of 16 sitesv17
- Minor Study sites: 14 to 16v16
- Minor Site details revised at 1 of 14 sitesv15
- Minor Primary completion date: Dec 2023 to Dec 31, 2023
- Study completion date: Dec 2024 to Dec 31, 2024
- Minor Study sites: 12 to 14v12
- Minor Study sites revised (12)v11
- Minor Study sites: 7 to 12
- Secondary endpoints: 8 to 9
- Notable Eligibility criteria expanded, about 24 wordsv9
- Minor Study sites: 15 to 7v8
- Minor Study sites: 5 to 15v7
- Minor Study sites: 3 to 5v6
- Minor Site details revised at 1 of 3 sitesv5
- Notable Eligibility criteria shortened, about 7 wordsv4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 3
- Start date changed from estimate of Feb 2019 to Dec 21, 2018
- Notable Start date: Dec 2018 to Feb 2019v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Disease-free survival
Timeframe: 5 years
Secondary (9)
Non-muscle invasive bladder cancer recurrence rate
Loco-regional control rate between study arms at the 12 week visit
Patterns of disease recurrence between study arms
Compare overall and bladder intact disease-free survival between study arms
Metastasis-free survival between study arms
Show 4 moreShow less
Number and severity of adverse events between study arms
Quality of Life between treatment arms using Functional Assessment of Cancer Therapy-Bladder Cancer (FACT-BL) questionnaire
Cost-effectiveness between study arms
Cost-utility between study arms
Arms and interventions
SurveillanceNo intervention
DurvalumabActive comparator
Drugs: Durvalumab
Sites
31 sites in 3 countries
Canada 15, Spain 8, United Kingdom 8